1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?

Mizuho raised CVS Health’s price target to $115 from $110, implying about 13% upside after the stock’s recent rally. The article argues CVS could rerate beyond that level, citing a forward P/E of 13.8x, expected 2026 EPS of $7.43, and potential for double-digit earnings growth in 2027. A move to a high-teens or 20x forward multiple could put the shares near $150.

Analysis

The move in CVS is less about the headline multiple and more about a regime shift in how the market underwrites the earnings stream: investors are starting to treat the company like a scaled managed-care / services compounder rather than a slow-growth retail-drug distributor. That matters because once the market accepts a higher quality-of-earnings framework, incremental beats can expand the multiple faster than EPS grows, especially when sentiment is still repairing from a prior de-rating.

The second-order winner is UNH, not because CVS’s re-rating directly impairs it, but because a broader rerating of diversified healthcare services would validate the sector’s premium versus traditional healthcare distribution. That said, CVS still screens as the cheaper way to express the same “defensive growth” theme, so relative value flows may continue to rotate from pure managed care into the newly credible turnaround name. The risk for CVS is not a missed quarter alone; it’s any sign that the Medicare-inflected improvement is transitory and not repeatable into the next earnings cycle.

The market is likely underestimating how quickly consensus can move once a stock exits the “prove-it” phase. If forward estimates continue to drift up over the next 1-2 quarters, the path to 18-20x forward earnings becomes more plausible than the current debate suggests, which is a meaningful change from a stock priced like a low-growth utility a few months ago. The contrarian risk is that the easy money has already been made in the rerating, and from here further upside requires both clean execution and an absence of margin pressure from reimbursement or mix shifts.

Key Decisions for Investors

• Maintain/add a tactical long CVS position for the next 1-2 quarters; base case is another leg higher if estimates keep rising, with 15-20% upside to the stock on modest multiple expansion, but trim if the stock approaches a high-teens forward multiple without estimate revisions.
• Pair trade: long CVS / short a lower-quality healthcare services laggard for relative-value exposure to the re-rating theme; this isolates multiple expansion from broad market beta and reduces risk if healthcare de-rates as a group.
• Buy CVS call spreads 3-6 months out to express upside toward the next consensus step-up while capping premium outlay; attractive if you expect volatility to compress after the latest rally.
• Use UNH as a hedge rather than a substitute: if CVS’s rerating is validated, UNH likely benefits from sector read-through, but CVS offers the cleaner beta to improving sentiment and multiple expansion from a lower starting point.
• Set a hard exit trigger if CVS loses the narrative of durable earnings acceleration over the next earnings print; the stock’s upside is now more dependent on estimate revisions than on pure sentiment, so a single disappointing guide could unwind a large portion of the recent move.